Veracyte Q1 revenue rises 21%, beats analyst estimates

Veracyte

05/05/2026 21:46

Overview

Cancer diagnostics firm's Q1 revenue rose 21% yr/yr, beating analyst expectations

Adjusted EPS for Q1 rose to $0.52 from $0.31 yr/yr

Company raised 2026 revenue and adjusted EBITDA margin guidance

Outlook

Veracyte raises 2026 total revenue guidance to $582 mln-$592 mln, up from $570 mln-$582 mln

Company raises 2026 testing revenue guidance to $570 mln-$580 mln, excluding new tests

Veracyte raises adjusted EBITDA margin guidance to greater than 26% for 2026

Result Drivers

DECIPHER AND AFIRMA GROWTH - Higher Q1 revenue and test volume driven by 30% growth in Decipher and 21% growth in Afirma tests

VOLUME INCREASE - Total test volume rose 17%, with Decipher test volume up 24% and Afirma up 12% yr/yr

GROSS MARGIN IMPROVEMENT - Gross margin increased to 73% from 69% a year earlier

Company press release: ID:nBw2z4kVha

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$139.07 mln
$130.04 mln (12 Analysts)
Q1 Net Income
$28.70 mln
Q1 Gross Margin
72.7%
Q1 Adjusted Operating Expenses
$64.63 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Veracyte Inc is $50.00, about 49.5% above its May 4 closing price of $33.45

The stock recently traded at 35 times the next 12-month earnings vs. a P/E of 37 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)